NEAT1: Culprit lncRNA linking PIG-C, MSLN, and CD80 in triple-negative breast cancer

Hussein, Nada H.; Eissa, Reda A.; Bruyn, Marco de; Tayebi, H.M. El

doi:10.1016/j.lfs.2022.120523

Cited by 3 publications

(3 citation statements)

References 59 publications

(106 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to TAMs correlation with tumor progression, there are some immunomodulatory proteins that have been reported in the last years to be overexpressed in various types of cancers, especially CD80 and mesothelin (MSLN). Furthermore, in the past few years, the role of non-coding RNAs in the pathogenesis of BC has been of significant importance and their correlation with immunomodulatory proteins, as shown in our previous study (Hussein et al, 2022). Interestingly, HOTAIR and MALAT1 are known to be the master regulators of tumor progression (Aiello et al, 2016).…”

Section: Discussionmentioning

confidence: 78%

A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach

Amer

Eissa²,

Tayebi³

2022

Front. Mol. Biosci.

Self Cite

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most common cancers, accounting for 2.3 million cases worldwide. BC can be molecularly subclassified into luminal A, luminal B HER2-, luminal B HER2+, HER2+, and triple-negative breast cancer (TNBC). These molecular subtypes differ in their prognosis and treatment strategies; thus, understanding the tumor microenvironment (TME) of BC could lead to new potential treatment strategies. The TME hosts a population of cells that act as antitumorigenic such as tumor-associated eosinophils or pro-tumorigenic such as cancer-associated fibroblasts (CAFs), tumor-associated neutrophils (TANs), monocytic-derived populations such as MDSCs, or most importantly “tumor-associated macrophages (TAMs),” which are derived from CD14+ monocytes. TAMs are reported to have the pro-inflammatory phenotype M1, which is found only in the very early stages of tumor and is not correlated with progression; however, the M2 phenotype is anti-inflammatory that is correlated with tumor progression and metastasis. The current study focused on controlling the anti-inflammatory activity in TAMs of hormonal, HER2+, and TNBC by epigenetic fine-tuning of two immunomodulatory proteins, namely, CD80 and mesothelin (MSLN), which are known to be overexpressed in BC with pro-tumorigenic activity. Long non-coding RNAs are crucial key players in tumor progression whether acting as oncogenic or tumor suppressors. We focused on the regulatory role of MALAT1 and HOTAIR lncRNAs and their role in controlling the tumorigenic activity of TAMs. This study observed the impact of manipulation of MALAT1 and HOTAIR on the expression of both CD80 and MSLN in TAMs of BC. Moreover, we analyzed the interlinkage between HOTAIR and MALAT1 as regulators to one another in TAMs of BC. The current study reported an upstream regulatory effect of HOTAIR on MALAT1. Moreover, our results showed a promising use of MALAT1 and HOTAIR in regulating oncogenic immune-modulatory proteins MSLN and CD80 in TAMs of HER2+ and TNBC. The downregulation of MALAT1 and HOTAIR resulted in the upregulation of CD80 and MSLN, which indicates that they might have a cell-specific activity in TAMs. These data shed light on novel key players affecting the anti-inflammatory activity of TAMs as a possible therapeutic target in HER2+ and TNBC.

show abstract

Section: Discussionmentioning

confidence: 78%

A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach

Amer

Eissa²,

Tayebi³

2022

Front. Mol. Biosci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mesothelin is a glycosylphosphatidylinositol-anchored cellsurface glycoprotein that is highly expressed in BC cells with a severely limited expression in normal tissues (144)(145)(146). A mesothelin-targeted thorium-227 conjugate, BAY 2287411 was tested for binding activity, radio stability, biodistribution, modeof-action, and antitumor potency using an in vitro cellular model, an in vivo orthotopic model, and a patient-derived xenograft model.…”

Section: Radionuclide Treatment In Breast Cancermentioning

confidence: 99%

The application of radionuclide therapy for breast cancer

Musket,

Davern,

Elam

et al. 2024

Front. Nucl. Med.

View full text Add to dashboard Cite

Radionuclide-mediated diagnosis and therapy have emerged as effective and low-risk approaches to treating breast cancer. Compared to traditional anatomic imaging techniques, diagnostic radionuclide-based molecular imaging systems exhibit much greater sensitivity and ability to precisely illustrate the biodistribution and metabolic processes from a functional perspective in breast cancer; this transitions diagnosis from an invasive visualization to a noninvasive visualization, potentially ensuring earlier diagnosis and on-time treatment. Radionuclide therapy is a newly developed modality for the treatment of breast cancer in which radionuclides are delivered to tumors and/or tumor-associated targets either directly or using delivery vehicles. Radionuclide therapy has been proven to be eminently effective and to exhibit low toxicity in eliminating both primary tumors and metastases, and even undetected tumors. In addition, the specific interaction between the surface modules of the delivery vehicles and the targets on the surface of tumor cells enables radionuclide targeting therapy, and this represents an exceptional potential for this treatment in breast cancer. This article reviews the development of radionuclide molecular imaging techniques that are currently employed for early breast cancer diagnosis and both the progress and challenges of radionuclide therapy employed in breast cancer treatment.

show abstract

“…NEAT1 can bind with multiple downstream miRNAs (sncRNA with approximately 22 nts) and regulate tumor growth and progression (Knutsen et al 2020 ). Therefore, targeting NEAT1-miRNAs suggests novel therapeutic targets in gynecologic cancers (Venkatesh et al 2021 ; Gu et al 2022 ; Hussein et al 2022 ). In this review, we summarized several NEAT1/miRNA/mRNA pathways that are critical in the pathogenesis of gynecologic cancers.…”

Section: Introductionmentioning

confidence: 99%

Emerging roles of the long non-coding RNA NEAT1 in gynecologic cancers

Farzaneh

Anbiyaiee

Najafi

et al. 2023

J. Cell Commun. Signal.

View full text Add to dashboard Cite

Gynecologic cancers are a worldwide problem among women. Recently, molecular targeted therapy opened up an avenue for cancer diagnosis and treatment. Long non-coding RNAs (lncRNAs) are RNA molecules (> 200 nt) that are not translated into protein, and interact with DNA, RNA, and proteins. LncRNAs were found to play pivotal roles in cancer tumorigenesis and progression. Nuclear paraspeckle assembly transcript 1 (NEAT1) is a lncRNA that mediates cell proliferation, migration, and EMT in gynecologic cancers by targeting several miRNAs/mRNA axes. Therefore, NEAT1 may function as a potent biomarker for the prediction and treatment of breast, ovarian, cervical, and endometrial cancers. In this narrative review, we summarized various NEAT1-related signaling pathways that are critical in gynecologic cancers. Graphical abstract

show abstract

NEAT1: Culprit lncRNA linking PIG-C, MSLN, and CD80 in triple-negative breast cancer

Cited by 3 publications

References 59 publications

A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach

A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach

The application of radionuclide therapy for breast cancer

Emerging roles of the long non-coding RNA NEAT1 in gynecologic cancers

Contact Info

Product

Resources

About